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Abstract
The influence of drug concentrations on the development of persistent
posttransplant hyperlipidemia was investigated in 82 patients who
received cyclosporin  A (CsA) and prednisone plus sirolimus (SRL)
(52) or azathioprine (AZA) (30) during the first year after transplanta-
tion. Blood levels of CsA and SRL, daily doses of AZA and pred-
nisone, and cholesterol, triglyceride, and glucose concentrations were
determined during each visit (pretransplant and 30, 60, 90, 120, 180,
and 360 days posttransplant). Persistent hyperlipidemia was defined
as one-year average steady-state cholesterol (CavCHOL) or triglyceride
(CavTG) concentrations above 240 and 200 mg/dL, respectively. Mean
cholesterol and triglyceride concentrations increased after transplan-
tation (P < 0.01) and were higher in patients receiving SRL compared
to AZA (P < 0.001). Patients receiving SRL showed a significantly
higher number of cholesterol (>229 or >274 mg/dL) and triglyceride
(>198 or >282 mg/dL) determinations in the upper interquartile
ranges. CsA and SRL interquartile ranges correlated with cholesterol
concentrations (P = 0.001) whereas only SRL interquartile ranges
correlated with triglyceride concentrations (P < 0.0001). Only pre-
transplant cholesterol concentration >205 mg/dL was independently
associated with development of persistent hypercholesterolemia
(CavCHOL >240 mg/dL, relative risk (RR) = 20, CI 3.8-104.6, P =
0.0004) whereas pretransplant triglyceride concentration >150 mg/dL
(RR = 7.2, CI 1.6-32.4, P = 0.01) or >211 mg/dL (RR = 19.8, CI 3.6-
107.9, P = 0.0006) and use of SRL (RR = 3, CI 1.0-8.8, P = 0.0049)
were independently associated with development of persistent hyper-
triglyceridemia (CavTG >200 mg/dL). Persistent hypercholesterole-
mia was more frequent among patients with higher pretransplant
cholesterol concentrations and was dependent on both CsA and SRL
concentrations. Persistent hypertriglyceridemia was more frequent
among patients with higher pretransplant triglyceride concentrations
and was dependent on SRL concentrations.
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Introduction
Immunosuppression has been associated
with hyperlipidemia after kidney transplan-
tation (1,2). While hypertriglyceridemia has
been associated with the use of azathioprine
(AZA) and steroid (3,4), the combination of
cyclosporin A (CsA) and prednisone (PRED)
has been predominantly associated with hy-
percholesterolemia after transplantation (5).
The efficacy of the addition of sirolimus
(SRL) to the CsA and PRED immunosup-
pressive regimen for the prevention of acute
kidney allograft rejection during the first
year after transplantation has been demon-
strated in phase III clinical trials (6,7). Com-
pared to other immunosuppressive regimens,
the addition of SRL to CsA and PRED im-
munosuppressive therapy has been associ-
ated with increased incidence and severity
of hypercholesterolemia and hypertriglycer-
idemia (8).
The mechanisms by which these drugs
interfere with lipid metabolism are different
and not completely known. Corticosteroids
produce insulin resistance, enhanced activ-
ity of acetyl-co-enzyme A carboxylase and
free fatty acid synthetase, increased hepatic
synthesis and secretion of very low-density
lipoprotein (VLDL), down-regulation of low
density lipoprotein (LDL) receptor activity,
increased activity of 3-hydroxy-3-methyl-
glutaryl co-enzyme A reductase, and inhibi-
tion of lipoprotein lipase, resulting in hyper-
cholesterolemia and hypertriglyceridemia
(9,10). CsA inhibits bile acid synthesis from
cholesterol and transport of cholesterol to
the intestines, binds to the LDL receptor,
increasing LDL cholesterol levels, reduces
post-heparin lipolytic activity, and decreases
lipoprotein lipase activity, effects that result
in impaired clearance of VLDL and LDL
cholesterol (11,12). SRL appears to alter the
insulin signaling pathway increasing adi-
pose tissue lipase activity and/or decreasing
lipoprotein lipase activity, resulting in in-
creased hepatic synthesis of triglycerides,
increased secretion of VLDL, and increased
hypertriglyceridemia (13).
All the effects of these drugs appear to be
dose or concentration dependent since dose
reductions performed routinely during the
first posttransplant year are associated with
parallel reductions in cholesterol and tri-
glyceride concentrations. Moreover, CsA,
SRL and PRED show synergistic pharmaco-
kinetic and pharmacodynamic interactions
(14). In animals and humans optimal effi-
cacy with minimal toxicity is achieved with
reduced doses of each drug (15). These drugs
are all preferentially metabolized by the cy-
tochrome P450 system (16). Therefore, the
individual contribution of each drug, regard-
ing dose and/or drug concentrations, to the
development of hyperlipidemia after trans-
plantation is not known and is difficult to
assess. To address this issue, we selected a
kidney transplant population with low pre-
transplant risk factors associated with hy-
perlipidemia, which received the same CsA-
and PRED-based immunosuppressive thera-
py, plus AZA or SRL, during the first year
after transplantation.
Subjects and Methods
Population
Between June 10, 1999 and October 31,
2000 we reviewed the charts of 125 trans-
planted patients who received CsA and PRED
immunosuppressive therapy without induc-
tion with monoclonal or polyclonal anti-
bodies. As adjunctive therapy 90 patients
received SRL and 35 patients received AZA.
Inclusion criteria were 13 years of age or
more and weight of more than 40 kg. Pa-
tients were also required to have total white
blood cell count ≥4.0 x 109/L, platelet count
≥100.0 x 109/L, fasting cholesterol ≤350
mg/dL (≤9.1 mmol/L) and/or fasting triglyc-
erides ≤500 mg/dL (≤5.65 mmol/L) during a
pretransplant screening evaluation. Women
of childbearing potential were required to
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have a negative pregnancy test before ad-
ministration of the study medication and to
practice medically approved birth control
throughout the study and for 3 months fol-
lowing discontinuation of SRL. Patients were
excluded if they had evidence of systemic
infection, a history of clinically significant
cardiac abnormalities or malignancy within
10 years of enrollment into the study and if
they had received treatment with an investi-
gational agent within 4 weeks of administra-
tion of SRL. Prophylaxis for Pneumocystis
carinii pneumonia and cytomegalovirus in-
fection was mandatory for all patients. The
local medical Ethics Committee approved
all protocols and the studies were performed
in accordance with the Declaration of
Helsinki and US Food and Drug Adminis-
tration guidelines for good clinical practice.
All patients signed a written informed con-
sent form after being informed of the nature
and details of the studies.
Immunosuppressive treatment and
monitoring
Prior to graft revascularization all pa-
tients received 1 g methylprednisolone.
Within 24 h after transplant surgery, patients
received an initial CsA dose of 8 to 10 mg/
day twice daily, 0.5 mg kg-1 day-1 of PRED
(maximum of 30 mg/day), and AZA (2 mg
kg-1 day-1) or SRL (a 6-mg loading dose
followed by a 2-mg fixed daily dose of SRL,
1 mg/mL; Wyeth-Ayerst Research, Radnor,
PA, USA), administered 4 h after the morn-
ing CsA dose. CsA doses were adjusted to
keep the whole blood through CsA concen-
trations between 200 and 400 ng/mL during
the first 4 weeks, 150 to 300 ng/mL from
week 5 to week 12, and between 100 and 200
ng/mL thereafter. To minimize SRL poten-
tiation of the nephrotoxic effects of CsA,
after the fourth post-transplant week patients
receiving SRL had their CsA doses adjusted
to keep blood concentrations within the lower
range of the therapeutic window, in contrast
to patients receiving AZA who had their
CsA doses adjusted to the middle or upper
range level.
Study design
To understand the impact of the exposure
to immunosuppressive drugs on lipid and
glucose profiles, we performed a retrospec-
tive analysis of the influence of blood CsA
and SRL concentrations, and daily PRED
doses on total serum cholesterol and triglyc-
erides, and on plasma glucose concentra-
tions up to 12 months after transplantation.
To assess these relationships, we selected
data from patients continuously receiving
either SRL or AZA in combination with CsA
and PRED up to the end of first post-trans-
plant year. Forty-three patients were excluded
from analysis, 10 due to pre-transplant (9
SRL, 1 AZA) and 7 due to post-transplant (5
SRL, 2 AZA) diabetes mellitus; 9 (SRL) due
to changes in initial immunosuppressive
therapy (anemia (2), graft loss (1), hyperlipi-
demia (1), lack of efficacy (2), urinary fis-
tula (1), parvovirus (1), and hemolytic ure-
mic syndrome (1)); 10 (SRL) due to early
withdrawal PRED; 3 due to graft losses (2
SRL and 1 AZA). Four patients (3 SRL and
1 AZA) died. Therefore, the data of 82 pa-
tients, 52 in the SRL group and 30 in the
AZA group, were used for analysis. Study
visits were performed pretransplant and 30,
60, 90, 120, 180, and 360 days after trans-
plantation. During each visit, AZA and PRED
doses, blood CsA and SRL levels and cho-
lesterol, triglycerides, and glucose concen-
trations were determined. The number of
patients requiring statins to control hyper-
lipidemia was also determined.
Bioanalytical methods
Whole blood CsA concentrations were
determined with the AxSYM CsA fluores-
cence polarization immunoassay kit (Abbott
Laboratories, Chicago, IL, USA), according
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to manufacturer directions. Performance was
assessed on the basis of a 3-point quality
control concentration range of low (70 ng/
mL), intermediate (300 ng/mL), and high
(600 ng/mL) concentrations. Whole blood
SRL concentrations were measured using a
validated HPLC method (17) and perfor-
mance was assessed using two quality con-
trol concentrations (10 and 50 ng/mL). Se-
rum cholesterol and triglyceride concentra-
tions and plasma glucose concentrations were
analyzed by an enzymatic and colorimetric
method using the COBAS MIRA-plus soft-
ware (Basel, Switzerland).
Diagnosis and treatment of hyperlipidemia
The diagnosis of hyperlipidemia was gen-
erally made based on a cholesterol concen-
tration above 240 mg/dL. At the time of the
diagnosis of hyperlipidemia, patients first
received dietary advice and instructions to
increase exercise. In case of persistence of
hyperlipidemia, treatment with statins (pra-
vastatin, fluvastatin, atorvastatin, and ceri-
vastatin) was introduced. The time of intro-
duction and the duration of treatment, as
well as the type and dose of statins were not
uniform among patients. All decisions were
made at the discretion of the attending phy-
sician. The lipid-lowering therapy was inter-
rupted in the presence of any adverse event
related to the statins, mostly hepatic and
skeletal muscle dysfunction. No patient re-
ceived fibrates and we did not observe any
case of rhabdomyolysis.
Concentration-effect relationships
Correlations between drug doses or con-
centrations and cholesterol, triglyceride or
glucose concentrations were calculated as
follows: 1) mean cholesterol, triglycerides
and glucose in patients receiving AZA or
SRL, regardless of blood SRL concentra-
tions; 2) fraction of patients receiving SRL
or AZA showing increasing cholesterol or
triglyceride concentrations (interquartile
ranges) and need for statins during the first
year after transplantation; 3) correlation be-
tween individual blood CsA and SRL con-
centrations and PRED doses and serum cho-
lesterol and triglyceride concentrations over
time; 4) correlations between CsA and SRL
concentrations, divided into quartiles, and
serum cholesterol and triglyceride concen-
trations; 5) univariate and multivariate analy-
ses were performed including demographic
characteristics, average steady-state drug
concentrations (Cav) and statin use to search
for independent risk factors associated with
the development of persistent posttransplant
hyperlipidemia (8). It has been demonstrated
in kidney transplant patients that a) CsA
concentrations and PRED doses decrease
over time; b) the administration of fixed
SRL doses produces a time-dependent in-
crease in blood concentrations after trans-
plantation; c) cholesterol and triglyceride
concentrations increase after transplantation
in patients receiving CsA-based immuno-
suppressive therapy, reaching a plateau
around 3 months posttransplant. These data
demonstrate that time is also a confounding
variable that may influence individual cho-
lesterol and triglyceride concentrations.
Therefore, instead of performing only simple
correlations at specific time points between
drug concentrations and cholesterol and tri-
glyceride levels we decided to take advan-
tage of a pharmacokinetic approach. CsA,
SRL, PRED, cholesterol, and triglyceride
concentrations were plotted over time dur-
ing the first 12 months of transplantation and
areas under the curve were measured using
the trapezoidal rule. Areas under the curve
were calculated using individual values ob-
tained on the occasion of each visit during
the first year of transplant and then divided
by 360 days to yield mean Cav. We then
defined patients as having persistent hyper-
cholesterolemia or hypertriglyceridemia if
they showed CavCHOL or CavTG values higher
than 240 and 200 mg/dL, respectively.
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Statistical analysis
Data concerning demographic character-
istics and drug or biochemical evaluations
were submitted to descriptive analysis using
means and standard deviation for continu-
ous variables and proportions for categori-
cal variables. Comparisons between groups
were performed by the unpaired two-tailed
Student t-test and by the chi-square test. A
general model for repeated measures was
applied, with time posttransplant and treat-
ment groups (AZA or SRL) used as co-
variates for within- and between-subject vari-
ability. Simple and multiple linear regres-
sion was used to correlate drug concentra-
tions and cholesterol and triglyceride con-
centrations. Two-way analysis of variance
was used to analyze the influence of differ-
ent concentration ranges (quartiles) of CsA
and SRL on cholesterol and triglyceride con-
centrations. Areas under the time-concen-
tration curves during the first year were cal-
culated using WinNonlin software (SCI soft-
ware, Salt Lake City, UT, USA). Multivari-
ate analysis and logistic regression analysis
were performed to identify risk factors for
the development of persistent hypercholes-
terolemia or hypertriglyceridemia. All sta-
tistical analyses were performed using SPSS
software (SPSS Inc., Chicago, IL, USA).
Results
Demographic characteristics
The demographic characteristics of the
patient population, shown in Table 1, are
representative of our general adult trans-
plant population. Mean age was 35.6 ± 10.5
years, mean body mass index (BMI) was 24
± 2.8 kg/m2, 72% of the patients were males
and 66% were white. The most frequent
causes of end-stage renal disease were
chronic glomerulonephritis (29%), hyper-
tension (21%) and others (50%). This was
predominantly a nonsensitized population
with a mean panel reactive antibody of 0.93
± 6% and mean human leukocyte antigen
mismatches of 3.6 ± 1.3, with a significant
difference when comparing patients receiv-
ing AZA or SRL (3.0 ± 0.5 vs 4.0 ± 1.5, P <
0.05), respectively. Regarding recognized
pretransplant risk factors, there were no sig-
nificant differences in mean cholesterol, tri-
glyceride or glucose concentrations, in mean
time on dialysis or in the percentage of pa-
tients with hypertension (Table 1). All pa-
tients tested negative for hepatitis C and B,
86% were positive for cytomegalovirus.
None of the patients was receiving lipid-
lowering agents before transplantation. Ex-
cept for a higher mean human leukocyte
antigen mismatch, there were no significant
differences in any demographic variables
between patients receiving SRL or AZA.
Table 1. Demographic characteristics of the transplant population.
Total (N = 82) SRL (N = 52) AZA (N = 30)
Age (years) 36.0 ± 10.5 37.0 ± 11.0 33.0 ± 10.0
BMI (kg/m2) 24.0 ± 3.0 24.0 ± 3.5 24.0 ± 1.0
Gender, N (%)
Male 59 (72) 39 (75) 20 (67)
Female 23 (28) 13 (25) 10 (33)
Ethnicity, N (%)
White 51 (62) 33 (63) 18 (60)
Black 15 (18) 8 (15) 7 (23)
Mulatto 16 (20) 11 (22) 5 (17)
Cause of ESRD, N (%)
Chronic glomerulonephritis 24 (29) 13 (25) 11 (37)
Hypertension 18 (22) 14 (27) 4 (13)
Polycystic kidney 2 (2) 2 (4) 0
Unknown origin 3 (4) 3 (6) 0
Other 35 (43) 20 (38) 15 (50)
HLA mismatch* 3.5 ± 1.5 4.0 ± 1.5 3.0 ± 0.5
Pre-transplant risk factors
Cholesterol (mg/dL) 172.0 ± 48.5 179.0 ± 52.0 159.0 ± 39.0
Triglycerides (mg/dL) 174.0 ± 101.0 185.0 ± 111.5 157.0 ± 79.0
Glycemia (mg/dL) 90.5 ± 23.0 94.5 ± 26.0 83.5 ± 13.0
Hypertension (N, %) 69 (84) 47 (90) 22 (73)
Dialysis time (months) 20.0 ± 17.0 22.0 ± 19.0 16.0 ± 12.0
SRL = sirolimus; AZA = azathioprine; BMI = body mass index; ESRD = end-stage
renal disease; HLA = human leukocyte antigen.
*P < 0.05 for SRL vs AZA (unpaired Student t-test).
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Immunosuppressive regimens
From day 30 (442 ± 100 vs 360 ± 99 mg/
day, P = 0.001) to day 360 (263 ± 74 vs 146
± 59 mg/day, P < 0.001), patients treated
with SRL were receiving significantly less
CsA to minimize potential drug interaction
as described in the Methods section. These
differences ranged from 19% at day 30 to
44% at day 360. This resulted in significant-
ly lower mean CsA concentrations from day
60 to day 360 in patients receiving SRL
compared to AZA (Table 2). As a result of a
faster taper in PRED doses, patients receiv-
ing SRL were receiving lower mean PRED
doses at day 90 compared to patients receiv-
ing AZA. Nevertheless, there were no sig-
nificant differences in mean PRED doses at
the end of 6 or 12 months after transplanta-
tion (Table 2). Although patients were re-
ceiving fixed 2-mg daily doses of SRL, high
inter- and intraindividual variability in blood
SRL concentrations were observed. Mean
blood SRL concentrations increased from
7.7 ± 3.7 ng/mL at day 30 to 10.2 ± 7.4 ng/
mL at day 120 (P = 0.057) with no further
increase until day 360, suggesting achieve-
ment of pharmacokinetic stability. There
were no significant temporal differences in
mean AZA doses from day 30 (130 ± 32.4
Table 3. Cholesterol, triglyceride and glucose concentrations during the first year of transplant in patients receiving sirolimus or azathioprine in
combination with cyclosporine and prednisone.
Days after transplant Cholesterol (mg/dL) Triglycerides (mg/dL) Glucose (mg/dL)
Totala SRL AZA Totala SRL AZA Total SRL AZA
0 172 ± 49 180 ± 52 159 ± 39 174 ± 101 185 ± 112 157 ± 79 91 ± 23 95 ± 26 84 ± 13b
30 279 ± 91 299 ± 102 244 ± 57b 217 ± 129 236 ± 134 186 ± 113 92 ± 15 92 ± 13 93 ± 18
60 259 ± 71 281 ± 71 220 ± 52b 247 ± 149 271 ± 170 206 ± 90b 95 ± 16 97 ± 17 91 ± 15
90 249 ± 59 265 ± 63 222 ± 37b 247 ± 162 279 ± 187 191 ± 80b 98 ± 18 101 ± 20 94 ± 14
120 240 ± 56 251 ± 64 222 ± 33b 253 ± 167 283 ± 193 198 ± 86b 98 ± 15 100 ± 17 94 ± 11
180 235 ± 62 247 ± 69 216 ± 41b 238 ± 125 265 ± 140 192 ± 77b 95 ± 19 99 ± 20 90 ± 14b
360 236 ± 62 252 ± 65 207 ± 44b 249 ± 169 296 ± 192 170 ± 74b 91 ± 14 92 ± 13 90 ± 15
SRL = sirolimus; AZA = azathioprine.
aP < 0.05 for the comparison of mean cholesterol or triglyceride concentrations between day 0 and day 360. bP < 0.05 for cholesterol, triglyceride
or glucose concentrations determined at individual study visits for patients receiving SRL vs AZA (unpaired Student t-test).
Table 2. Comparison of the mean immunosuppressive drug doses and concentrations in patients receiving
sirolimus and azathioprine.
Days after transplant Sirolimus (N = 52) Azathioprine (N = 30)
CsA PRED SRL CsA PRED AZA
(ng/mL) (mg/day) (ng/mL) (ng/mL) (mg/day) (mg/day)
30 286.7 ± 110.2 23.5 ± 4.7 7.7 ± 3.7 324.6 ± 96.5 25.7 ± 5.2 130.0 ± 32.4
60 166.0 ± 77.5a 14.3 ± 4.7 8.1 ± 4.4 216.6 ± 78 16.0 ± 4.2 124.2 ± 33.1
90 155.2 ± 87.1a 11.1 ± 2.3 9.1 ± 5.1 196.0 ± 75.1 14.3 ± 4.1b 124.2 ± 33.1
120 131.4 ± 52.0b 10.6 ± 1.9 10.2 ± 7.4 182.6 ± 66.6 10.0 ± 1.9 119.2 ± 38.1
180 131.0 ± 57.4b 10.2 ± 2.4 7.4 ± 3.9 162.8 ± 62.6 9.7 ± 1.3 122.5 ± 36.2
360 102.1 ± 70.8a 9.2 ± 4.7 10.7 ± 7.0 187.8 ± 76.5 9.8 ± 2.0 118.5 ± 32.2
CsA = cyclosporin A; PRED = prednisone; SRL = sirolimus; AZA = azathioprine.
aP < 0.05 and bP < 0.001 for CsA concentrations or daily PRED doses of patients receiving sirolimus
compared to those of patients receiving azathioprine (unpaired Student t-test).
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mg/day) to day 360 (118.5 ± 32.2 mg/day).
Concentration-effect relationships
Mean weight increased from 64.5 ± 12.5
kg pretransplant to 72.4 ± 13.0 kg at day
360, an increase of 12%, with no significant
differences comparing SRL and AZA pa-
tients. Mean pretransplant cholesterol (172
± 49 mg/dL) and triglyceride (174 ± 101 mg/
dL) concentrations increased after transplan-
tation, reaching maximum levels at day 60
(260 ± 71 mg/dL) and 120 (253 ± 167 mg/
dL), respectively (Table 3, P < 0.05). Using
a general linear model for repeated measures
we observed that, at any given visit after
transplantation, mean cholesterol and tri-
glyceride concentrations were higher in pa-
tients receiving SRL compared to patients
receiving AZA (Table 3, P < 0.001). How-
ever, there was no significant difference in
the pattern or magnitude of increase in cho-
lesterol and triglyceride concentrations dur-
ing the study period, using visit and treat-
ment group (SRL or AZA) in a two-way
interaction model (P = 0.25). There were no
significant differences between mean pre-
transplant glucose concentrations and the
concentration observed at day 360. Patients
receiving SRL showed significantly higher
pretransplant (95 ± 26 vs 84 ± 13 mg/dL, P <
0.05) and day 180 (99 ± 20 vs 90 ± 14 mg/dL,
P < 0.05) mean glucose concentrations com-
pared to patients receiving AZA.
We then divided cholesterol and triglyc-
eride concentrations into quartiles and com-
pared the proportion of measurements in
each quartile according to treatment (AZA
or SRL) and study visit (30, 90, 180, and 360
days). Patients receiving SRL showed a sig-
nificantly higher proportion of cholesterol
(Figure 1A) and triglyceride (Figure 1B)
concentrations in the upper interquartile
ranges. Also, the use of statin increased from
30 to 360 days and was significantly higher
in patients receiving SRL compared to AZA
(Figure 1C). In four patients (3 SRL, 1 AZA)
Figure 1. Comparison of the proportion of serum cholesterol (A) and
triglyceride (B) concentrations, according to interquartile ranges, in pa-
tients receiving azathioprine (AZA) or sirolimus (SRL). Unpaired independ-
ent Student t-test was used to determine statistical significance between
mean in each study visit. C, Comparison of the proportion of patients in
each group (AZA or SRL) receiving statins. Exact chi-square test was used
to determine statistical significance.
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Since linear correlations were not strong
and PRED doses were not associated with
either cholesterol or triglyceride concentra-
tions, we then stratified CsA (<25-115, 116-
163, 164-221, and >221 ng/mL) and SRL (0
(patients receiving AZA), 0.1-6.4, 6.5-9.5,
and >9.5 ng/mL) concentrations into quartiles
and searched for a combined effect of both
drug concentrations on cholesterol and tri-
glyceride concentrations using two-way anal-
ysis of variance. CsA (P < 0.0001) and SRL
(P < 0.0001) interquartile ranges correlated
with cholesterol concentrations and the com-
bined effect of both drugs was also signifi-
cantly associated with cholesterol concen-
trations (P = 0.001, Figure 2A). On the other
hand, only SRL interquartile ranges showed
a significant correlation with triglyceride
concentrations (P < 0.0001, Figure 2B).
To better understand the relationship be-
tween pretransplant risk factors, drug expo-
sure, and the pattern and magnitude of cho-
lesterol and triglyceride increase and need of
statins after transplantation we calculated
for each patient CavCsA, CavSRL, CavPRED,
CAVCHOL, and CavTG using the linear trap-
ezoidal rule. Using linear regression analy-
sis, age (r2 = 0.05, P = 0.05), hypertension (r2
= 0.05, P = 0.04), pretransplant cholesterol
concentration (r2 = 0.23, P < 0.001), use of
SRL (r2 = 0.06, P = 0.03), and use of statin (r2
= 0.2, P < 0.001) were significantly associ-
ated with CavCHOL. Similarly, age (r2 = 0.08,
P = 0.01), hypertension (r2 = 0.06, P = 0.04),
pretransplant triglyceride concentrations (r2
= 0.15, P = 0.001), use of SRL (r2 = 0.09, P
= 0.006), CavSRL (r2 = 0.07, P < 0.02), and
use of statin (r2 = 0.15, P < 0.001) were
significantly associated with CavTG. Using
multiple stepwise linear regression analysis,
only age and pretransplant cholesterol con-
centration were independently and signifi-
cantly associated with CavCHOL (r2 = 0.34, P
< 0.0001). Similarly, pretransplant triglyc-
eride concentration was independently and
significantly associated with CavTG (r2 = 0.3,
P < 0.0001).
Figure 2. Combined effect of cyclosporin and sirolimus
whole blood concentrations (according to interquartile
ranges) on serum cholesterol (A) and triglyceride (B) con-
centrations. AZA = azathioprine; SRL = sirolimus; CsA =
cyclosporin A. Two-way analysis of variance was used to
determine statistical significance.
statin treatment had to be discontinued due
to adverse events, mainly muscle pain and
elevated creatine-phosphokinase.
The correlations between CsA or SRL
concentrations, PRED doses and cholesterol
concentrations (CsA: r2 = 0.02, P = 0.002;
SRL: r2 = 0.0, P = 0.8; PRED: r2 = 0.026, P <
0.001) or triglyceride (CsA: r2 = 0.0, P = 0.9;
SRL: r2 = 0.3, P = 0.005; PRED: r2 = 0.001,
P = 0.5) were poor. Using stepwise forward
multivariate analysis, including CsA and SRL
concentrations and PRED doses, the vari-
able independently associated with choles-
terol was CsA concentration (r2 = 0.054, P <
0.001) and the variable independently asso-
ciated with triglyceride concentrations was
SRL concentration (r2 = 0.03, P = 0.005).
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The influence of demographic param-
eters and drug exposures on CavCHOL and
CavTG is shown in Table 4. Age, hyperten-
sion, pretransplant cholesterol concentration,
use of SRL, and need for statin were signifi-
cantly associated with higher mean CavCHOL.
Hypertension, BMI, pretransplant triglycer-
ide concentration, use of SRL, and CavSRL
were significantly associated with higher
CavTG. Finally, we used binary logistic re-
gression analysis to identify risk factors as-
sociated with hypercholesterolemia (>240
mg/dL) or hypertriglyceridemia (>200 mg/
dL). For hypercholesterolemia, there was a
correlation with age (r2 = 0.22, P < 0.007),
pretransplant cholesterol concentration (r2 =
0.36, P = 0.0001) and pretransplant triglyc-
eride concentration (r2 = 0.19, P = 0.02.
CavSRL (r2 = 0.1, P = 0.07) and CavPRED (r2 =
0.11, P = 0.07) were marginal. For hypertri-
glyceridemia, there was a correlation with
pretransplant triglyceride concentration (r2
= 0.29, P = 0.001) and CavSRL (r2 = 0.15, P =
0.03), with age (r2 = 0.11, P = 0.06) reaching
marginal significance. In a multivariate bi-
nary logistic regression analysis, only pre-
transplant cholesterol concentration above
205 mg/dL was independently associated
with development of hypercholesterolemia
(relative risk, RR = 20, CI 3.8-104.6, P =
0.0004) whereas pretransplant triglyceride
concentration above 150 mg/dL (RR = 7.2,
CI 1.6-32.4, P = 0.01) or above 211 mg/dL
(RR = 19.8, CI 3.6-107.9, P = 0.0006) and
use of SRL (RR = 3, CI 1.0-8.8, P = 0.0049)
were independently associated with devel-
opment of hypertriglyceridemia.
Discussion
As shown in Table 1, this transplant popu-
lation can be considered to be at low risk to
develop hyperlipidemia. Most patients are
young, white, non-obese, and non-diabetic,
with a relatively short period on dialysis and
with normal pretransplant cholesterol and
triglyceride concentrations (1). The high
prevalence of males and hypertensive pa-
tients is typical of any transplant population
but there were no significant differences
between patients receiving SRL or AZA that
might lead to the development of hyperlipi-
demia.
CsA doses and concentrations were lower
in the SRL group than in the AZA group
because of the synergistic pharmacokinetic/
Table 4. Mean cholesterol (CavCHOL) and triglyceride (CavTG) according to risk factors during the first 12
months after transplantation.
Risk factor CavCHOL (mg/dL) CavTG (mg/dL)
Group (AZA/SRL) 218 ± 32 253 ± 52a 191 ± 64 267 ± 13a
Age (<36.5 years>) 222 ± 39 258 ± 51a 219 ± 129 259 ± 108
BMI (<23.9, kg/m2>) 234 ± 45 246 ± 52 209 ± 71 268 ± 147b
Dialyses time (<15.5 months>) 238 ± 46 242 ± 52 231 ± 130 249 ± 109
Pretransplant cholesterol (<166 mg/dL>) 223 ± 41 260 ± 50a 224 ± 101 258 ± 137
Pretransplant triglyceride (<150 mg/dL>) 231 ± 41 251 ± 55 200 ± 98 286 ± 127a
Gender (male/female) 234 ± 48 255 ± 49 240 ± 108 238 ± 148
Ethnicity (white/non-white) 244 ± 50 234 ± 47 246 ± 120 229 ± 120
Rejection (yes/no) 242 ± 41 240 ± 50 295 ± 199 234 ± 108
CavCsA (<150 ng/mL>) 247 ± 54 234 ± 43 254 ± 117 225 ± 122
CavSRL (<5.5 ng/mL>) 232 ± 48 248 ± 48 218 ± 98 262 ± 137
CavPRED (<11.7 mg/day>) 246 ± 50 230 ± 46 246 ± 131 229 ± 99
Hypertension (yes/no) 246 ± 46 209 ± 53b 252 ± 124 175 ± 65b
Statin (yes/no) 260 ± 51 216 ± 34a 282 ± 139 188 ± 62a
AZA = azathioprine; SRL = sirolimus; BMI = body mass index; CsA = cyclosporin A; PRED = prednisone.
aP < 0.01 and bP < 0.05 for CavCHOL and CavTG (unpaired independent Student t-test).
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pharmacodynamic interaction between CsA
and SRL (15). Moreover, a fast taper of
PRED was performed in the SRL group
during the first 3 months, with the dose
remaining unchanged after this period. Nev-
ertheless, as previously demonstrated, there
was an increase in cholesterol and triglycer-
ide concentrations peaking between 60 and
90 days, with a subsequent reduction up to
one year after transplantation (Table 3), com-
patible with reduction of drug dosages and
specific treatment with statins (8).
Compared to patients receiving AZA,
patients receiving SRL, although showing
lower concentrations of CsA and a faster
taper of PRED, had higher mean concentra-
tions of cholesterol and triglycerides during
the first year (Table 2). Except for higher
mean values, there were no unusual patterns
in the elevation of cholesterol and triglycer-
ide levels since in a two-way (patient vs
visit) interaction model there were no sig-
nificant differences between patients receiv-
ing SRL or AZA. This was further con-
firmed when we looked at the distribution of
patients according to cholesterol or triglyc-
eride concentration (Figure 1), which showed
that a higher proportion of patients were
above the 50 and 75% interquartile range in
the SRL group compared to the AZA group.
A large fraction of patients in the SRL group
also received statins to reduce cholesterol
and triglyceride concentrations but this strat-
egy was not fully effective due to the magni-
tude of the increase and/or the relative po-
tency of the statin used (18-20).
Knowing that patients receiving SRL dis-
played higher mean cholesterol and triglyc-
eride concentrations we then searched for
concentration-effect relationships. Since all
patients were submitted to a similar CsA and
PRED dose reduction and were receiving
fixed doses of SRL, this was only possible
due to the considerable inter- and intraindi-
vidual variability in both CsA and SRL con-
centrations (21). Using a linear model and
considering patients receiving AZA to have
SRL concentrations equal to zero, we ob-
served a significant and independent but
weak correlation between individual CsA
concentrations and posttransplant cholesterol
concentrations (r2 = 0.054, P < 0.001) and
between SRL and triglyceride concentra-
tions (r2 = 0.03, P = 0.005). Prednisone doses
did not show such correlations perhaps be-
cause all patients received comparable doses
and underwent a similar dose reduction over
the first year of transplantation. By dividing
CsA and SRL concentration into interquar-
tile ranges and comparing them with choles-
terol or triglyceride concentration in a two-
way interaction model we observed that while
cholesterol concentration after transplant
correlated with CsA and SRL concentration
ranges (P = 0.001, Figure 2A), triglyceride
concentration correlated exclusively with
SRL concentrations (P < 0.0001, Figure 2B).
This is in agreement with studies comparing
CsA-based versus SRL-based immunosup-
pressive regimens (22,23).
Perhaps more important than correlating
individual drug concentrations or ranges,
which changed over the first year according
to a predefined protocol, with cholesterol or
triglyceride concentrations after transplant,
is to clearly identify risk factors in patients
with persistent hyperlipidemia, with or with-
out specific treatment, during the first year
of transplantation. Individual one-year areas
under the time-concentration curves were
calculated for cholesterol and triglyceride as
well as for CsA and SRL and PRED doses.
Again, using multiple stepwise linear re-
gression analysis, only age and pretrans-
plant cholesterol concentration were inde-
pendently and significantly associated with
CavCHOL (r2 = 0.34, P < 0.0001) and pretrans-
plant triglyceride concentration was inde-
pendently and significantly associated with
CavTG (r2 = 0.3, P < 0.0001).
By dividing the population according to
demographic risk factors and drug exposure
below or above median values we identified
that age, hypertension, pretransplant choles-
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terol concentration, use of SRL, and need for
statin were significantly associated with
higher mean CavCHOL. Similarly, hyperten-
sion, BMI, pretransplant triglyceride con-
centration, use of SRL, and CavSRL were
significantly associated with higher CavTG.
Finally, a binary forward multiple logistic
regression analysis considering patients hav-
ing persistent hyperlipidemia after transplan-
tation (CavCHOL > 240 mg/dL or CavTG > 200
mg/dL) showed that only pretransplant cho-
lesterol concentrations above 205 mg/dL
were independently associated with the de-
velopment of persistent hypercholesterole-
mia (RR = 20, CI 3.8-104.6, P = 0.0004). On
the other hand, pretransplant triglyceride
concentrations above 150 mg/dL (RR = 7.2,
CI 1.6-32.4, P = 0.01) or above 211 mg/dL
(RR = 19.8, CI 3.6-107.9, P = 0.0006) and
use of SRL (RR = 3, CI 1.0-8.8, P = 0.0049)
were independently associated with devel-
opment of persistent hypertriglyceridemia
(14,21,24,25).
The cellular and molecular mechanisms
of the effects of SRL resulting in hyperlipi-
demia are not completely known. There are
initial data suggesting that the molecular
target of rapamycin is involved in intracellu-
lar insulin signaling and lipid synthesis
(13,26,27). Furthermore, increased levels of
apolipoprotein CIII, an inhibitor of lipopro-
tein lipase (28), and reduced catabolism of
apolipoprotein B100-containing lipoproteins
(29) may also be involved in the mechan-
isms responsible for hyperlipidemia in pa-
tients receiving SRL.
Overall, these data suggest that in pa-
tients receiving CsA-based immunosuppres-
sive therapy with tightly controlled steroid
dosage and taper, persistent hypercholester-
olemia is more frequent among patients with
higher pretransplant cholesterol concentra-
tions and is dependent on both CsA and SRL
concentrations. Hypertriglyceridemia is more
frequent among patients with higher pre-
transplant triglyceride concentrations and is
dependent on SRL concentrations. This in-
formation may help to select immunosup-
pressive drug regimens for kidney trans-
plant candidates.
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